For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
Abbvie Inc (NYSE: ABBV) closed the day trading at $177.44 down -5.62% from the previous closing price of $188.00. In other words, the price has decreased by -$5.62 from its previous closing price. On the day, 12.2 million shares were traded. ABBV stock price reached its highest trading level at $187.645 during the session, while it also had its lowest trading level at $176.64.
Ratios:
For a better understanding of ABBV, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 60.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.37. For the most recent quarter (mrq), Quick Ratio is recorded 0.64 and its Current Ratio is at 0.76. In the meantime, Its Debt-to-Equity ratio is 49.22 whereas as Long-Term Debt/Eq ratio is at 45.44.
On April 22, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $210.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 31 ’25 when Stewart Jeffrey Ryan sold 58,832 shares for $210.08 per share. The transaction valued at 12,359,504 led to the insider holds 53,234 shares of the business.
Stewart Jeffrey Ryan bought 58,832 shares of ABBV for $12,359,897 on Mar 31 ’25. On Mar 14 ’25, another insider, Reents Scott T, who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 17,644 shares for $212.34 each. As a result, the insider received 3,746,527 and left with 11,577 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 313430016000 and an Enterprise Value of 378320551936. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 75.66, and their Forward P/E ratio for the next fiscal year is 12.68. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.46 while its Price-to-Book (P/B) ratio in mrq is 220.71. Its current Enterprise Value per Revenue stands at 6.595 whereas that against EBITDA is 13.824.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.50, which has changed by 0.079647064 over the last 52 weeks, in comparison to a change of 0.11241627 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $218.66, while it has fallen to a 52-week low of $153.58. The 50-Day Moving Average of the stock is -8.94%, while the 200-Day Moving Average is calculated to be -6.29%.
Shares Statistics:
Over the past 3-months, ABBV traded about 7.96M shares per day on average, while over the past 10 days, ABBV traded about 8167360 shares per day. A total of 1.77B shares are outstanding, with a floating share count of 1.76B. Insiders hold about 0.11% of the company’s shares, while institutions hold 73.99% stake in the company. Shares short for ABBV as of 1745971200 were 19795764 with a Short Ratio of 2.49, compared to 1743379200 on 17142376. Therefore, it implies a Short% of Shares Outstanding of 19795764 and a Short% of Float of 1.1199999999999999.
Dividends & Splits
ABBV’s forward annual dividend rate is 6.38, up from 6.38 a year ago. Against a Trailing Annual Dividend Yield of 0.03393617The stock’s 5-year Average Dividend Yield is 3.96.
